Serum sclerostin level might be a potential biomarker for arterial stiffness in prevalent hemodialysis patients. (July 2016)

• Record Type: Journal Article
• Authors: Jin, Shi; Zhu, Mingli; Yan, Jiayi; Fang, Yan; Lu, Renhua; Zhang, Weiming; Zhang, Qi; Lu, Jiayue; Qi, Chaojun; Shao, Xinghua; Zhang, Haifen; Jiang, Rong; Ni, Zhaohui
• Is Part Of: Biomarkers in medicine. Volume 10:Number 7(2016)
• Page Start: 689
• Page End: 699
• Publication Date: 2016-07
• Subjects: hemodialysis -- pulse wave velocity -- sclerostin; Biochemical markers -- Periodicals; 610.28
• DOI: 10.2217/bmm-2016-0031
• Languages: English
• ISSNs: 1752-0363

Abstract

Aim: To explore the relationship between circulating sclerostin levels and pulse wave velocity (PWV) in prevalent hemodialysis (HD) patients.Patients & methods: 154 HD patients were enrolled and examined for serum sclerostin level, carotid-femoral pulse wave velocity (cf-PWV), abdominal artery calcification and calcaneus bone marrow density.Results: Serum sclerostin level was significantly elevated in patients with arterial stiffness. Univariate correlation showed serum sclerostin level significantly correlated with intact parathyroid hormone level, cf-PWV and calcaneus bone marrow density. Multiple linear regression analysis in patients with parathyroid hormone ≤300 pg/ml showed that pulse pressure, logAACs and serum sclerostin level were significant independent factors for cf-PWV.Conclusion: Serum sclerostin level was significantly associated with PWV in prevalent HD patients without hyperparathyroidism.